By the Numbers
Milestones & Market Analysis
US Market Analysis for (R)-9b
| Therapeutics | Target Market | Price/year | Market Penetration | Peak Annual Revenue |
|---|---|---|---|---|
| (R)-9b in Prostate Cancer | 25%: 58,000 (of total 233,000) | $84,000 | 25% | $1,218 M |
| (R)-9b in Lung Cancer | 20%: 42,000 (of total 210,000) | $84,000 | 10% | $336 M |
| (R)-9b in TNBCs | 15%: 36,000 (of total 240,000) | $84,000 | 20% | $576 M |
| Peak Annual Revenue | $2,130 M* | |||
*Does not include world market analysis (China, India, Europe) where patent application is filed.
US/World Market Analysis — Comparison
| Therapeutics | Company | Price/month | Annual Revenue | Revenue 2022 |
|---|---|---|---|---|
| Enzalutamide (Xtandi) | Astellas and Pfizer | $7,450 | $2,100 M | $4,710 M |
| Abiraterone (Zytiga) | Johnson & Johnson | $9,593 | $2,260 M | $3,500 M |